News & Updates

Among individuals living with depression and anxiety, the use of electronic wearable devices (EWDs) might be an indicator of their intent to lose weight and in turn may be valuable as a starting point for clinical interactions aimed at improving physical health, according to a recent study.

During Singapore’s coronavirus disease 2019 (COVID-19) lockdown, older adults experienced a decrease in depressive symptoms accompanied by growing feelings of loneliness and lower physical activity (PA), according to a recent study.

By using digital biomarkers that reflect behavioural and physiological patterns, consumer-grade wearable devices have the potential to screen for people with or at risk of depression, according to a recent Singapore study.

Results of a randomized, double-blind, placebo-controlled trial show no benefit with mirtazapine, given with normal clinical care, for treatment of clinically significant agitation in patients with dementia compared with placebo, with a potentially higher mortality observed with the use of mirtazapine.

Three surrogate measures of insulin resistance are positively associated with incident major depressive disorder among adults with no history of depression or anxiety disorder, results of the Netherlands Study of Depression and Anxiety (NESDA) have shown. Moreover, the development of prediabetes between study enrolment and 2-year visit also predicts incident major depressive disorder.